SG11201910197SA - Compounds for treating dengue virus infection and other viral infections - Google Patents

Compounds for treating dengue virus infection and other viral infections

Info

Publication number
SG11201910197SA
SG11201910197SA SG11201910197SA SG11201910197SA SG 11201910197S A SG11201910197S A SG 11201910197SA SG 11201910197S A SG11201910197S A SG 11201910197SA SG 11201910197S A SG11201910197S A SG 11201910197SA
Authority
SG
Singapore
Prior art keywords
compounds
international
boston
avenue
brookline
Prior art date
Application number
Inventor
Priscilla Yang
Wenlong Lian
Nathanael Gray
Nicholas Kwiatkowski
Jinhua Wang
Jaebong Jang
Original Assignee
Dana Farber Cancer Inst Inc
Harvard College
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dana Farber Cancer Inst Inc, Harvard College filed Critical Dana Farber Cancer Inst Inc
Publication of SG11201910197SA publication Critical patent/SG11201910197SA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/42—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/16—Peri-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/16—Peri-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

International Patent Classification: C07D 209/30 (2006.01) C07D 209/42 (2006.01) (21) International Application Number: PCT/US2018/032849 (22) International Filing Date: 15 May 2018 (15.05.2018) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 62/506,588 15 May 2017 (15.05.2017) US (71) Applicants: DANA-FARBER CANCER INSTITUTE, INC. [US/US]; 450 Brookline Avenue, Boston, MA 02215 (US). PRESIDENT AND FELLOWS OF HARVARD COLLEGE [US/US]; 17 Quincy Street, Cambridge, MA 02138 (US). (72) Inventors: YANG, Priscilla, L.; 26 Greenview Avenue, Boston, MA 02130 (US). LIAN, Wenlong, L.; 155 Strath- more Road, Apt. #1, Boston, MA 02135 (US). GRAY, Nathanael, S.; 26 Greenview Avenue, Boston, MA 02130 (US). KWIATKOWSKI, Nicholas, Paul; 12 Kilsyth Road, #2, Brookline, MA 02445 (US). WANG, Jinhua; 103 Loring Avenue, Winchester, MA 01890 (US). JANG, Jaebong; 521 Heath Street, Brookline, MA 02467 (US). (74) Agent: ZHANG, Wei; Wolf, Greenfield & Sacks, P.C., 600 Atlantic Avenue, Boston, MA 02210-2206 (US). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, (54) Title: COMPOUNDS FOR TREATING DENGUE VIRUS INFECTION AND OTHER VIRAL INFECTIONS + compound, co- 0V2 NGC M01=1 Remove inoculum, wash and add Pre-incubation incubation fresh media 1 4 , 1 -45 min 0 1 h Figure 2A 6x113 5 4x10 5 .4 0ta DV2 NGC M01=1 E ▪ 2x10 5- -2 -1 0 log[K786-9730]/01 K786-0739 -2x10 5 RC Y Single-cycle yield by plaque formation assay 4 24 h 00 O O (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 22 November 2018 (22.11.2018) WIP01 PCT oimitia °nolo Holoffinonuno oimIE (10) International Publication Number WO 2018/213365 Al (57) : The present disclosure provides antiviral (e.g., anti -Dengue virus) agents, such as compounds of Formula (I). Also provided are pharmaceutical compositions and kits of the compounds of Formula (I). Further provided are methods and uses of the antiviral agents (e.g., the compounds of Formula (I); and compounds K786-9739, S4105, C200-5340, G199-0398, C200-9144, S7337, S1633, and C066-4182, and derivatives thereof) for treating or preventing a viral infection Dengue fever). The antiviral agents (e.g., may inhibit the entry of a virus into a cell by, e.g., inhibiting the fusion between the envelope of the virus and the membrane of the cell. [Continued on next page] WO 2018/213365 Al MIDEDIM011111 11111111E1010010E11111101111111101111111111111111111 TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Published: — with international search report (Art. 21(3))
SG11201910197S 2017-05-15 2018-05-15 Compounds for treating dengue virus infection and other viral infections SG11201910197SA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762506588P 2017-05-15 2017-05-15
PCT/US2018/032849 WO2018213365A1 (en) 2017-05-15 2018-05-15 Compounds for treating dengue virus infection and other viral infections

Publications (1)

Publication Number Publication Date
SG11201910197SA true SG11201910197SA (en) 2019-11-28

Family

ID=64274883

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201910197S SG11201910197SA (en) 2017-05-15 2018-05-15 Compounds for treating dengue virus infection and other viral infections

Country Status (3)

Country Link
US (1) US20200360381A1 (en)
SG (1) SG11201910197SA (en)
WO (1) WO2018213365A1 (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019222349A1 (en) * 2018-05-15 2019-11-21 Dana-Farber Cancer Institute, Inc. Compounds for treating dengue virus infections and other infections
CA3134814A1 (en) 2019-03-26 2020-10-01 Ventyx Biosciences, Inc. Tyk2 pseudokinase ligands
AU2020378345A1 (en) 2019-11-08 2022-06-02 Ventyx Biosciences, Inc. TYK2 pseudokinase ligands
MX2022006281A (en) 2019-11-25 2022-06-08 Amgen Inc Heterocyclic compounds as delta-5 desaturase inhibitors and methods of use.
EP4138844A1 (en) * 2020-04-21 2023-03-01 Lexicon Pharmaceuticals, Inc. 4-(3-(pyridin-3-yl)pyrazolo[1,5-a]pyrimidin-5-yl)piperazine for use in the the treatment of cov-229e or cov-oc43 coronaviruses infections
EP3939585A4 (en) * 2020-05-20 2022-03-02 Syntekabio, Inc. Preventive or therapeutic composition for severe acute respiratory syndrome coronavirus type 2 infectious disease
CN112939947B (en) * 2021-03-05 2023-07-18 中国医科大学 PARP7 small molecule inhibitor compound and application thereof
WO2022232518A1 (en) * 2021-04-29 2022-11-03 Unm Rainforest Innovations Calxinin compositions and method for treating viral infections
CN116102549A (en) * 2021-11-09 2023-05-12 暨南大学 5-aldehyde heterocyclic amide compound and application thereof
WO2023082044A1 (en) * 2021-11-09 2023-05-19 暨南大学 5-formyl heterocyclic amide compound and use thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7781478B2 (en) * 2004-07-14 2010-08-24 Ptc Therapeutics, Inc. Methods for treating hepatitis C
JP2012522806A (en) * 2009-04-06 2012-09-27 ピーティーシー セラピューティクス，インコーポレーテッド Indole derivatives and methods for antiviral treatment

Also Published As

Publication number Publication date
WO2018213365A1 (en) 2018-11-22
US20200360381A1 (en) 2020-11-19

Similar Documents

Publication Publication Date Title
SG11201910197SA (en) Compounds for treating dengue virus infection and other viral infections
SG11201806863WA (en) Tetracyclic pyridone compounds as antivirals
SG11201808944QA (en) Therapeutic compounds useful for the prophylactic or therapeutic treatment of an hiv virus infection
SG11201809344QA (en) Process for synthesizing 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)-pyridin-3-yl)methoxy)benzaldehyde
SG11201900077QA (en) 1,3-dihydroxy-phenyl derivatives useful as immunomodulators
SG11201809064QA (en) Chimeric neurotoxins
SG11201805300QA (en) Heterocyclic compounds as immunomodulators
SG11201901700UA (en) Biaryl compounds useful as immunomodulators
SG11201907544VA (en) Jak inhibitors containing a 4-membered heterocyclic amide
SG11201811338VA (en) A novel botulinum neurotoxin and its derivatives
SG11201805044WA (en) Compounds useful as kinase inhibitors
SG11201810423XA (en) Pd-1 / pd-l1 inhibitors for cancer treatment
SG11201805940QA (en) Benzopyrazole compounds and analogues thereof
SG11201901658PA (en) Beta-lactamase inhibitor compounds
SG11201908604YA (en) Fused imidazo-piperidine jak inhibitor compound
SG11201907356SA (en) Piperidine-substituted mnk inhibitors and methods related thereto
SG11201901633WA (en) 7-substituted sulfonimidoylpurinone compounds for the treatment and prophylaxis of virus infection
SG11201900545TA (en) Pharmaceutical compounds
SG11201811442UA (en) Formulation of a peptide vaccine
SG11201908114UA (en) Pyrimidopyrimidinones useful as wee-1 kinase inhibitors
SG11201806868TA (en) Compositions and methods for protecting against airborne pathogens and irritants
SG11201909429VA (en) 3-(((((2s,5r)-2-carbamoyl-7-oxo-1,6-diazabicyclo[3.2.1]octan-6-yl)oxy)sulfonyl)oxy)-2,2-dimethylprop noate derivatives and related compounds as perorally administered profrugs of beta-lactamase inhibitors for treating bacterial infections
SG11201906436VA (en) Novel heterocyclic compound, its preparation method, and pharmaceutical composition comprising the same
SG11201810454YA (en) Use of an anti-pd-1 antibody in combination with an anti-cd30 antibody in lymphoma treatment
SG11201901374WA (en) Antibiotic compounds